Andrew ElBardissi
Partner @ Deerfield
New York, United States
Andrew ElBardissi is a Series C investor at Deerfield in New York focused on Medical and Biotechnology. Andrew ElBardissi - Partner @ Deerfield
- Total investments:
- 14
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Andrew ElBardissi invests in
Stages Andrew ElBardissi invests in
Countries Andrew ElBardissi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 7 (50%)
- Biotechnology 7 (50%)
- Health Care 6 (43%)
- Medical Device 4 (29%)
- Health Diagnostics 2 (14%)
Stage
- Series C 6 (43%)
- Series A 2 (14%)
- Venture - Series Unknown 2 (14%)
- Series B 1 (7%)
- Series G 1 (7%)
Country
- United States 8 (57%)
- Israel 2 (14%)
- Italy 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $110M / Series C / Feb 21, 2024 | ||
| Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease. | $145M / Series A / Jun 07, 2023 | ||
| Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $24M / Series G / Apr 14, 2023 | ||
| Pleno Inc. is a multi-omic instrument platform company democratizing biological target detection for clinical testing and biomedical research. The company’s proprietary Hypercoding™ technology leverages signal processing techniques from the telecommunications industry to deliver targeted biological information at unprecedented scale, precision, andperformance. | $40M / Series A / Oct 12, 2022 | ||
| We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $75M / Series B / Jul 20, 2022 | ||
| Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinicallyvalidated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness. | $120M / Venture - Series Unknown / Apr 12, 2022 | ||
| V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave hasdeveloped a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices. | $98M / Series C / Dec 16, 2021 | ||
| Encodia provides in-depth information on cellular processes to enable personalized medicine.Our technology reverse translates peptide sequence information into a DNA library. This means scientists can scale their research more easily to accelerate novel approaches to our most challenging diseases.Encodia was established on January 1, 2015 inSan Diego, California. | $75M / Series C / Jan 27, 2021 | ||
| V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave hasdeveloped a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices. | $28M / Series C / Sep 22, 2020 | ||
| Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories.Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all. | $121M / Series C / Jul 29, 2020 | ||
| See all 14 investments → | |||
Co-Investors
About Deerfield
Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.
Deerfield Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexander Karnal
Partner and Managing Director
|
|||
|
Andrew ElBardissi
Partner
|
|||
Bryan Sendrowski
Partner
|
|||
Cameron Wheeler
Principal
|
|||
Elise Wang
Partner, Head of Private Equity Capital Markets
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Andrew ElBardissi invest in?
Andrew ElBardissi invests primarily in Medical, Biotechnology and Health Care startups, most often at Series C and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Andrew ElBardissi?
Public channels for Andrew ElBardissi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Andrew ElBardissi last invest?
The most recent investment recorded for Andrew ElBardissi closed in Feb 2024. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
